A phase I trial of cyclosporine for hospitalized patients with COVID-19
BACKGROUND COVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine storm. Cyclosporine A (CSA) is a calcineurin inhibito...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2022-06-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.155682 |